Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 50, Issue 4, 2011, Pages 395-405

  Findling, Robert L ^a   Childress, Ann C ^b   Cutler, Andrew J ^c   Gasior, Maria ^d   Hamdani, Mohamed ^d   Ferreira Cornwell, M Celeste ^d   Squires, Liza ^d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Center for Psychiatry and Behavioral Medicine Inc   (United States)

^c Florida Clinical Research Center LLC   (United States)

^d SHIRE   (United States)

Author keywords

ADHD; lisdexamfetamine dimesylate (LDX); stimulant; treatment

Indexed keywords

LISDEXAMFETAMINE; PLACEBO;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DECREASED APPETITE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HEART RATE; HUMAN; INSOMNIA; IRRITABILITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MOOD CHANGE; MULTICENTER STUDY; NAUSEA; NOSE CONGESTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULSE PRESSURE; QT INTERVAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REGRESSION ANALYSIS; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; VOMITING; WEIGHT; XEROSTOMIA;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOXICITY; FEMALE; HUMANS; MALE; PERSONALITY ASSESSMENT; PSYCHOMETRICS; QUALITY OF LIFE; TREATMENT OUTCOME; UNITED STATES;

EID: 79952967310     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2011.01.007     Document Type: Article

References (39)

1. M. Green, M. Wong, and D. Atkins Diagnosis of attention deficit/hyperactivity disorder Technical review 3 1999 US Department of Health and Human Services, Agency for Health Care Policy and Research Rockville (MD) AHCPR publication 99-0050
2. R.H. Weisler Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD Expert Opin Pharmacother 6 2005 1003 1018
3. American Academy of Pediatrics Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder Pediatrics 108 2001 1033 1044
4. G. Polanczyk, M.S. de Lima, B.L. Horta, J. Biederman, and L.A. Rohde The worldwide prevalence of ADHD: a systematic review and metaregression analysis Am J Psychiatry 164 2007 942 948 (Pubitemid 46972911)
5. H. Schubiner, and S. Katragadda Overview of epidemiology, clinical features, genetics, neurobiology, and prognosis of adolescent attention-deficit/hyperactivity disorder Adolesc Med State Art Rev 19 2008 209 215 vii
6. V.A. Harpin The effect of ADHD on the life of an individual, their family, and community from preschool to adult life Arch Dis Child 90 Suppl 1 2005 i2 i7
7. M.I. Reiff, and M.T. Stein Attention-deficit/hyperactivity disorder evaluation and diagnosis A practical approach in office practice Pediatr Clin North Am 50 2003 1019 1048 (Pubitemid 37204483)
8. C.L. Bagwell, B.S. Molina, W.E. Pelham Jr., and B. Hoza Attention-deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence J Am Acad Child Adolesc Psychiatry 40 2001 1285 1292 (Pubitemid 32995796)
9. S. Katragadda, and H. Schubiner ADHD in children, adolescents, and adults Prim Care 34 2007 317 341 (Pubitemid 47102412)
10. S. Pliszka AACAP Work Group on Quality Issues Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder J Am Acad Child Adolesc Psychiatry 46 2007 894 921
11. L.L. Greenhill, S. Pliszka, and M.K. Dulcan Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults J Am Acad Child Adolesc Psychiatry 41 2 Suppl 2002 26S 49S
12. M. Pennick Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine Neuropsychiatr Dis Treat 6 2010 317 327
13. J. Biederman, S. Krishnan, Y. Zhang, J.J. McGough, and R.L. Findling Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study Clin Ther 29 2007 450 463 (Pubitemid 46924786)
14. R.L. Findling, A.C. Childress, S. Krishnan, and J.J. McGough Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder CNS Spectr 13 2008 614 620
15. L.A. Adler, D.W. Goodman, S.H. Kollins 303 Study Group Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder J Clin Psychiatry 69 2008 1364 1373
16. R. Weisler, J. Young, G. Mattingly, J. Gao, L. Squires, L. Adler 304 Study Group Long-Term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder CNS Spectr 14 2009 573 585
17. J. Biederman, S.W. Boellner, A. Childress, F.A. Lopez, S. Krishnan, and Y. Zhang Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study Biol Psychiatry 62 2007 970 976 (Pubitemid 47562371)
18. G.J. DuPaul, T.J. Power, A.D. Anastopoulos, and R. Reid ADHD Rating ScaleIV: Checklists, Norms, and Clinical Interpretation 1998 Guilford Press New York, NY
19. W. Guy Clinical global impressions ECDEU Assessment Manual for Psychopharmacology 1976 US Department of Health, Education, and Welfare; Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch Rockville, MD 218 222
20. Youth Quality of Life InstrumentResearch Version (YQOL-R) 2002 University of Washington Seattle, WA
21. American Psychiatric Association Attention-deficit and disruptive behavior disorders In: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition 2000 American Psychiatric Association Washington, DC Text Revision
22. P. Mattos, and L.A. Rohde The Kiddie-SADSPresent and Lifetime Version J Atten Disord 11 2007 100
23. D.E. Faries, I. Yalcin, D. Harder, and J.H. Heiligenstein Validation of the ADHD Rating Scale as a clinician administered and scored instrument J Atten Disord 5 2001 107 115 (Pubitemid 33794656)
24. D.L. Patrick, T.C. Edwards, and T.D. Topolski Adolescent quality of life, part II: initial validation of a new instrument J Adolesc 25 2002 287 300 (Pubitemid 41115228)
25. T.C. Edwards, C.E. Huebner, F.A. Connell, and D.L. Patrick Adolescent quality of life, part I: conceptual and measurement model J Adolesc 25 2002 275 286 (Pubitemid 41115227)
26. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH E14 http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129357.pdf Accessed November 24, 2010
27. R. Escobar, A. Montoya, and P. Polavieja Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder J Child Adolesc Psychopharmacol 19 2009 253 263
28. P. Svanborg, G. Thernlund, P.A. Gustafsson, B. Hagglof, L. Poole, and B. Kadesjo Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naive Swedish children and adolescents Eur Child Adolesc Psychiatry 18 2009 240 249
29. L. Bastiaens Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic Psychiatr Q 79 2008 133 137
30. A.R. Perwien, C.J. Kratochvil, D.E. Faries, B.S. Vaughan, T. Spencer, and R.T. Brown Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes? J Child Adolesc Psychopharmacol 16 2006 713 724 (Pubitemid 46175427)
31. J.H. Newcorn, T.J. Spencer, J. Biederman, D.R. Milton, and D. Michelson Atomoxetine treatment in children and adolescents with attention-deficit/ hyperactivity disorder and comorbid oppositional defiant disorder J Am Acad Child Adolesc Psychiatry 44 2005 240 248 (Pubitemid 40299837)
32. L.S. Matza, A.M. Rentz, and K. Secnik The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder J Dev Behav Pediatr 25 2004 166 174 (Pubitemid 38960833)
33. J. Biederman, F.A. Lopez, S.W. Boellner, and M.C. Chandler A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder Pediatrics 110 2002 258 266 (Pubitemid 34833008)
34. P.J. Ambrosini, F.R. Sallee, F.A. Lopez, L. Shi, and M.A. Michaels A community assessment, open-label study of the safety, tolerability, and effectiveness of mixed amphetamine salts extended release in school-age children with ADHD Curr Med Res Opin 22 2006 427 440 (Pubitemid 44296767)
35. P.A. Ahmann, F.W. Theye, R. Berg, A.J. Linquist, A.J. Van Erem, and L.R. Campbell Placebo-controlled evaluation of amphetamine mixturedextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects Pediatrics 107 2001 E10
36. S.B. Wigal, S.H. Kollins, A.C. Childress, L. Squires 311 Study Group A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder Child Adolesc Psychiatry Ment Health 3 2009 17
37. T.E. Wilens, P.G. Hammerness, and J. Biederman Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder J Clin Psychiatry 66 2005 253 259 (Pubitemid 40314334)
38. D.J. Safer Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorder J Child Adolesc Psychopharmacol 2 1992 279 290
39. R.L. Findling, E.J. Short, and M.J. Manos Short-term cardiovascular effects of methylphenidate and Adderall J Am Acad Child Adolesc Psychiatry 40 2001 525 529 (Pubitemid 32374269)